Benefits of Attending:
- Network with experts interested in the treatment of cholangiocarcinoma
- Learn about novel targets for the treatment of cholangiocarcinoma guided by advancements in understanding biomarkers and pathophysiology
- Obtain expert recommendations for best practices in managing and treating patients with cholangiocarcinoma
Agenda Highlights:
- Exploring the Current State of Cholangiocarcinoma
- Have We Maximized the Current Standard of Care?
- How Pathophysiological Advancements Inform Rationale for Drug Development
- Evolving Management Approaches in Cholangiocarcinoma
- Panel Discussion: Challenging Cases in Cholangiocarcinoma
Program Chair:
Ghassan K. Abou-Alfa, MD, MBA
Professor of Medicine
Weill Medical College of Cornell University
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
Benefits of Attending:
- Cognize the role of pembrolizumab in MSI-high/dMMR tumors
- Identify later lines of therapy based on first-line therapy
- Discuss pancreatic cancer agents under investigation
- Dissect accumulating data, like the POLO trial
Agenda Highlights:
- The Emerging Role of Neoadjuvant Therapy in Pancreatic Cancer
- Treatment Considerations in Pancreatic Cancer: Chemotherapy, Radiotherapy, and Sequencing
- Advances in Targeted Therapy in Pancreatic Cancer
- Discussion of Investigational Treatments in Pancreatic Cancer
- Audience Q&A
Program Chair:
Shubham Pant, MD
Associate Professor
Department of Investigational Cancer Therapeutics
Associate Professor
Department of Gastrointestinal Medical Oncology
Associate Director
Department of Pancreatic Cancer Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Benefits of Attending:
- Utilize insights from leading clinical experts to appropriately test for actionable DDR-associated mutations in patients with pancreatic cancer
- Acquire knowledge from several experts in pancreatic cancer simultaneously via case-based panel discussions
- Discuss challenging clinical cases with colleagues and leaders in clinical research for pancreatic cancer
- Navigate the changing treatment paradigm for targeted therapy in pancreatic cancer with evidence-based reasoning
Agenda Highlights:
- Importance of the DNA Damage Response and Rationale for PARP Inhibition in Pancreatic Cancer
- Molecular Testing Considerations for Patients With Pancreatic Cancer
- Clinical Data of PARP Inhibition in the Management of Pancreatic Cancer
- Future Directions for PARP Inhibitors and Other DDR-Focused Therapies in Pancreatic Cancer
Program Chair:
Eileen M. O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Benefits of Attending:
- Highlight emerging data on the genomic and temporal heterogeneity of molecular resistance
- Discuss novel agents and strategies that may refine the therapeutic landscape
- Survey positive and negative trials investigating HER2-targeted agents
- Rationalize the use of HER2 targeted treatment approaches
- Investigate the challenges facing the use of trastuzumab
Agenda Highlights:
- Exploring HER2 in Gastrointestinal Cancers
- Tumor Testing Techniques for Detecting HER2 in Your Practice
- Therapeutic Agents Targeting HER2 and Associated Challenges
- Medical Crossfire® Discussion: Challenging Cases in Gastric Cancer and other GI Malignancies
- Evidence-Based Summary and Audience Q&A Session
Program Chair:
David H. Ilson, MD, PhD
Professor of Medicine
Weill Medical College of Cornell University
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
